John SullivanBolyai - Hepion Pharmaceuticals Chief Medical Officer
| HEPA Stock | USD 1.31 0.06 4.38% |
Executive
Dr. John Z. SullivanBolyai M.D., is Chief Medical Officer of the Company. From August 2014 until January 2015, Dr. Sullivan Bolyai was the Executive Director of Infectious Disease clinical research at Merck Co. Inc. where he oversaw multiple HCV protocols in all three phases of clinical development. From June 2007 until August 2014, he was the VicePresident of Clinical Research at Idenix Pharmaceuticals Inc. where he managed all medical aspects of the HIV and HCV programs. Additionally, he was responsible for the transition of Idenixs clinical team to Merck, which acquired Idenix. Prior to joining Idenix, Dr. SullivanBolyai worked at Anadys Pharmaceuticals on hepatitis C and at Valeant Pharmaceuticals International on Valeants nucleotide prodrug for the treatment of chronic hepatitis B infection. Previously, he held various medical and operations positions at Biomeasure and Serono Laboratories in Massachusetts, working on coagulation, immunomodulatory, endocrine, and gastrointestinal compounds. He began his career with HoffmannLa Roche where he worked on a variety of compounds for the treatment of bacterial infections, HCV and HIV. Dr. SullivanBolyai received an MD, MPH from the University of Washington in Seattle. He completed his infectious diseases fellowship training at the Childrens Orthopedic Hospital and Medical Center, Seattle, WA, followed by academic positions at UCLA and the University of Illinois. since 2015.
| Age | 76 |
| Tenure | 9 years |
| Address | 399 Thornall Street, Edison, NJ, United States, 08837 |
| Phone | 732 902 4000 |
| Web | https://www.hepionpharma.com |
Hepion Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.7221) % which means that it has lost $0.7221 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7126) %, meaning that it created substantial loss on money invested by shareholders. Hepion Pharmaceuticals' management efficiency ratios could be used to measure how well Hepion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -2.57. The current year's Return On Capital Employed is expected to grow to -3.36. At present, Hepion Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 24 M, whereas Non Currrent Assets Other are forecasted to decline to about 222.4 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Scott Gottesman | AVROBIO | N/A | |
| Robert Yang | Elevation Oncology | N/A | |
| Theresa Lowry | Zura Bio Limited | 50 | |
| Robert Sweeney | Ocean Biomedical | 59 | |
| Esq CPA | Ocean Biomedical | 59 | |
| Kirsten Dupuis | AVROBIO | N/A | |
| Verender Badial | Zura Bio Limited | 51 | |
| Michael Howell | Zura Bio Limited | 47 | |
| Kimberly Davis | Zura Bio Limited | 56 | |
| Andreas Kouri | AVROBIO | N/A | |
| MD MBA | Ocean Biomedical | 59 | |
| David Brady | Zura Bio Limited | N/A | |
| Kevin CPA | Enveric Biosciences | 60 | |
| Gary Whale | Zura Bio Limited | 50 | |
| Candice Masse | Elevation Oncology | N/A | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| Steven JD | AVROBIO | 62 | |
Management Performance
| Return On Equity | -1.71 | ||||
| Return On Asset | -0.72 |
Hepion Pharmaceuticals Leadership Team
Elected by the shareholders, the Hepion Pharmaceuticals' board of directors comprises two types of representatives: Hepion Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hepion. The board's role is to monitor Hepion Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hepion Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hepion Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BSc BSc, CEO Pres | ||
| Patrick Mayo, Senior Pharmacology | ||
| John Cavan, Chief Officer | ||
| Sharen Pyatetskaya, Director Relations | ||
| Todd MD, Chief Officer | ||
| Daniel Trepanier, Senior Development | ||
| Daren Ure, Chief Officer | ||
| MD FACP, Scientific Director | ||
| John SullivanBolyai, Chief Medical Officer | ||
| Launa Aspeslet, Chief Officer | ||
| Stephen MD, Member Director |
Hepion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hepion Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.71 | ||||
| Return On Asset | -0.72 | ||||
| Current Valuation | (5.38 M) | ||||
| Shares Outstanding | 5.47 M | ||||
| Shares Owned By Insiders | 0.30 % | ||||
| Shares Owned By Institutions | 13.66 % | ||||
| Number Of Shares Shorted | 63.97 K | ||||
| Price To Earning | (3.01) X | ||||
| Price To Book | 0.67 X | ||||
| EBITDA | (45.19 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hepion Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hepion Pharmaceuticals' short interest history, or implied volatility extrapolated from Hepion Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Hepion Stock analysis
When running Hepion Pharmaceuticals' price analysis, check to measure Hepion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hepion Pharmaceuticals is operating at the current time. Most of Hepion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hepion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hepion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hepion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is Hepion Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.32) | Return On Assets (0.72) | Return On Equity (1.71) |
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.